<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

NeoTract Announces 100,000 Patients Treated for Enlarged Prostate with UroLift® System

Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2

Read More

NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate

Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms

Read More

Data Suggest That Men Should Resolve to Address Their BPH Symptoms in 2019

NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options

Read More

12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases

PLEASANTON, Calif. – December 14, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of 12-month data from the multi-center prospective MedLift™ Study of the UroLift® System treatment for Benign Prostatic Hyperplasia (BPH) in patients with an obstructive median lobe. Results were published in Prostate Cancer and Prostatic Diseases, a Nature Publishing Group journal.

Read More

NeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate

PLEASANTON, Calif. – November 5, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH).

Read More

NeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement

PLEASANTON, Calif. – October 29, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the company received the Phoenix 2018 Emerging Growth Company Award at the 25th Annual Phoenix Medical Device and Diagnostic Conference in Laguna Beach, Calif. sponsored by the firm Wilson Sonsini Goodrich & Rosati.

Read More

NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged Prostate

PLEASANTON, Calif. – Oct. 15, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

Read More

NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

PLEASANTON, Calif. – Sept. 24, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

Read More

NeoTract Announces Multiple Data Presentations from Studies of UroLift® System Treatment for Enlarged Prostate at the World Congress of Endourology

PLEASANTON, Calif. – Sept. 17, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that new clinical data from numerous studies of the UroLift® System for patients with benign prostatic hyperplasia (BPH) will be presented at the 36th World Congress of Endourology (WCE) 2018 Annual Conference taking place September 20-23 in Paris.

Read More

NeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)

WAYNE, PA – June 08, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and patient outcomes of the UroLift System compared to transurethral resection of the prostate (TURP). The study demonstrated that replacing the current standard of care for men suffering symptoms of benign prostatic hyperplasia (BPH) with the UroLift® System could save the National Health System approximately (NHS) £27 million in costs associated with post-surgical complications.

Read More